Epi-transcriptomic small RNA modifications as predictive signatures for therapy response in Diffuse Large B cell Lymphoma.
Diagnostics, Human R&D, Innovation
KWF Kanker Bestrijding – Grant ID 2016-I
1 March 2017 to 1 March 2021
Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin lymphoma in adults with 1500 newly diagnosed patients/year in the Netherlands. DLBCL treatment involves standard immuno-chemotherapy resulting in cure rates of only 40-60%. Current diagnostic approaches provide very limited guidance to identify refractory DLBCL patients who may benefit from other therapies. Various strategies to stratify DLBCL patients based on gene-expression profiling, including mRNA/microRNA expression profiling and genome-wide sequencing analysis have confirmed the striking heterogeneity of the disease, but may provide insufficient support for clinical decisions by themselves. Identification and validation of novel molecular predictors for DLBCL treatment response are therefore needed both in daily clinical practice and to support programs on novel treatment strategies. Therefore, the project set out to advance cancer diagnostics by exploring the potential of small non-coding RNA modifications by identifying novel molecular markers for early detection of treatment-resistant cancers. Within that project, GenomeScan provided both: the expertise in Next Generation Sequencing techniques and sequencing services.
This work was funded by the Dutch Cancer Society, with a project number 2016-I.